Background
HIV is a retrovirus having ss RNA as the genetic material, which gets converted into ds DNA in the presence of reverse transcriptase (RT) enzyme. RT has been found the most attractive target for development of anti HIV-1 agents. Its inhibition is considered as one of the most practical approaches to prevent HIV infection.
Methods
NNRTIs are non-competitive inhibitors and bind at allosteric site. Designing of non nucleoside analogs of pyrimidine as NNRTIs has been done on the basis of Lipinski’s Rule of Five & using the software DS 3.0. The molecules have been docked with HIV-RT using DS 3.0 in order to generate computational data and assess their suitability.
Anzeige
Results
Docking experiments have shown good interaction of non nucleoside analogs of pyrimidine as NNRTIs. Analysis of the docking results revealed that these molecules adopted butterfly conformations while interacting at NNIBP of HIV-1 RT & formed hydrogen bonds with amino acids, Lys101, Lys103, Tyr181, Tyr318 and π-stacking interactions with Tyr181, Tyr188, Phe227 and Trp229.
Conclusion
The molecular modeling revealed the interaction level of these molecules comparable to that of nevirapine. Hence, we predict these molecules as potential NNRTIs against HIV-1 RT.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.